查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1824014

TCR-T 疗法市场报告：2031 年趋势、预测与竞争分析

TCR-T Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2025年至2031年，全球TCR-T疗法市场将以12.1%的复合年增长率成长，难治性/復发性黑色素瘤、滑膜肉瘤、多发性骨髓瘤和肺癌等市场将迎来发展机会。该市场的主要驱动力是免疫肿瘤学资金的增加以及基因工程技术的不断进步。

  • 根据Lucintel的预测，自体肿瘤预计在预测期内将出现高速成长。
  • 从应用来看，难治性和復发性黑色素瘤预计将出现最高的成长。
  • 按地区划分，预计亚太地区将在预测期内实现最高成长。

TCR-T疗法市场的新趋势

TCR-T 疗法市场正随着新趋势的出现而不断演变，这些趋势正在重塑癌症治疗格局。这些趋势主要由技术进步、个人化医疗以及免疫治疗方法研究的活性化推动。以下是正在改变 TCR-T 疗法市场的五个关键趋势：

  • 个人化癌症治疗：TCR-T 疗法正朝着更个人化的方向发展，利用每位患者独特的癌症特征来开发标靶治疗。这一趋势涉及分离患者癌细胞特有的肿瘤抗原，并开发靶向这些抗原的 T 细胞。随着 TCR-T 疗法变得更加精准，治疗效果将更加显着，副作用将最小化，治疗成功率也会提高。
  • 固体癌研究日益受到关注：虽然TCR-T疗法传统上在治疗血液系统癌症方面更为成功，但研究人员也越来越关注固体癌。固体癌因其复杂的微环境和难以有效靶向抗原而面临更大的挑战。然而，TCR-T技术的持续创新使得肺癌、乳癌和大肠直肠癌等固体癌的标靶治疗成为可能，极大地拓展了TCR-T疗法在癌症治疗中的潜在应用。
  • 全球临床试验的扩张：临床试验的扩张是TCR-T疗法市场的另一个主要趋势。随着生技公司、学术机构和监管机构之间合作的加强，临床试验的数量和范围都在不断扩大，尤其是在中国和印度等新兴市场。临床试验对于证明TCR-T疗法的安全性和有效性至关重要，随着临床试验的增多，核准和广泛应用的途径也变得更加清晰。
  • TCR-T 疗法与其他免疫疗法的整合：TCR-T 疗法正越来越多地与其他免疫疗法（包括 CAR-T 疗法、免疫查核点抑制剂和癌症疫苗）联合应用。其目标是同时靶向多种途径，以增强整体治疗效果。结合不同的免疫疗法可以更有效地激活免疫系统对抗癌症，这可能为患者带来更持久、更长期的益处。
  • 生产和可扩展性的进步：TCR-T 疗法面临的关键挑战之一是个人化 T 细胞的生产过程复杂且成本高昂。然而，T 细胞生产的可扩展性正在取得进展，包括利用自动化和人工智慧来简化流程。这些进步有望降低生产成本，并使 TCR-T 疗法更广泛地普及，从而惠及更广泛的患者群体。

TCR-T 疗法市场正在被个人化治疗、关注固体癌、全球临床试验、联合治疗和製造业进步等趋势再形成，这些趋势有望提高 TCR-T 疗法的可及性、有效性和可负担性，推动其进入主流癌症治疗领域。

TCR-T疗法市场的最新趋势

受研究、临床试验和监管核准的推动，TCR-T 疗法市场正在快速成长。近期，TCR-T 疗法的疗效和可近性取得了显着进展。以下五项关键进展塑造了 TCR-T 疗法市场的现状。

  • FDA核准TCR-T 疗法：美国食品药物管理局(FDA) 近期核准了数种用于治疗血癌（包括黑色素瘤和白血病）的 TCR-T 疗法。这些核准标誌着 TCR-T 疗法商业化迈出的重要一步，并为患者提供了获得尖端治疗的途径。 FDA 对 TCR-T 疗法的核准流程正在加快，尤其是在危及生命的癌症领域，反映出人们对该技术潜力的日益核准。
  • 固体癌治疗的突破：TCR-T疗法在固体癌治疗的应用已取得重大进展。从历史上看，TCR-T疗法对血液系统癌症更有效，但新的策略正在出现，以克服固体癌带来的挑战。针对肺癌、大肠直肠癌和胰腺癌的临床试验已显示出良好的疗效，这可能显着拓展TCR-T疗法的市场，并使其成为更广泛患者的治疗选择。
  • TCR-T 疗法开发的国际合作：在 TCR-T 疗法的开发中，国际伙伴关係正变得越来越普遍。生物技术公司、学术机构和医疗保健提供者之间的合作有助于简化临床试验流程并共用知识和资源。此类伙伴关係也有助于降低 TCR-T 疗法的开发成本，使其更经济实惠且易于取得。美国、中国和欧洲公司之间的重要合作正在加速该领域的全球进步。
  • 同种异体TCR-T疗法的开发：TCR-T市场的一个重大发展是转向同种异体TCR-T疗法的转变。这些治疗方法使用来自健康捐赠者的T细胞，而非患者自身的T细胞。这种方法有望降低生产成本，并使TCR-T疗法更广泛地普及。开发现成的同种异体TCR-T製剂是一个重要的研究领域，因为它有可能显着提高治疗的扩充性和可负担性。
  • TCR-T 製造技术的进步：製造技术的进步正在提高 TCR-T 疗法的生产效率和成本效益。包括自动化和细胞培养创新在内的新技术正在简化 T 细胞的培养和改造流程。这些进步有望解决当前扩充性的挑战并降低生产成本，最终使更多患者更容易获得 TCR-T 疗法。

TCR-T 疗法市场的最新趋势，包括 FDA核准、固体癌治疗的突破、国际合作、同种异体疗法的发展以及製造过程的进步，正在重塑癌症治疗的未来。这些发展推动了 TCR-T 疗法的广泛应用，使其更接近成为全球更多患者的可行治疗方案。

目录

第一章执行摘要

第二章 市场概况

  • 背景和分类
  • 供应链

第三章：市场趋势及预测分析

  • 产业驱动力与挑战
  • PESTLE分析
  • 专利分析
  • 法规环境

4. 全球TCR-T疗法市场类型

  • 概述
  • 按类型分析吸引力
  • 自体移植：趋势与预测（2019-2031）
  • 同种异体：趋势与预测（2019-2031）

5. 全球TCR-T疗法市场（依应用）

  • 概述
  • 按用途分析吸引力
  • 难治性与復发性黑色素瘤：趋势与预测（2019-2031）
  • 滑膜肉瘤：趋势与预测（2019-2031）
  • 多发性骨髓瘤：趋势与预测（2019-2031）
  • 肺癌：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031）

第六章 区域分析

  • 概述
  • TCR-T 疗法市场（按地区）

7. 北美TCR-T疗法市场

  • 概述
  • 北美TCR-T疗法市场类型
  • 北美TCR-T疗法市场（按应用）
  • 美国TCR-T疗法市场
  • 墨西哥的TCR-T疗法市场
  • 加拿大TCR-T疗法市场

8. 欧洲TCR-T疗法市场

  • 概述
  • 欧洲TCR-T疗法市场类型
  • 欧洲TCR-T疗法市场应用
  • 德国TCR-T疗法市场
  • 法国TCR-T疗法市场
  • 西班牙TCR-T疗法市场
  • 义大利TCR-T疗法市场
  • 英国TCR-T疗法市场

9. 亚太地区TCR-T疗法市场

  • 概述
  • 亚太地区TCR-T疗法市场（按类型）
  • 亚太TCR-T疗法市场（依应用）
  • 日本的TCR-T疗法市场
  • 印度TCR-T疗法市场
  • 中国TCR-T疗法市场
  • 韩国TCR-T疗法市场
  • 印尼的TCR-T疗法市场

第十章世界其他地区（ROW）TCR-T 疗法市场

  • 概述
  • 按类型分類的 ROW TCR-T 疗法市场
  • 按应用分類的 ROW TCR-T 疗法市场
  • 中东TCR-T疗法市场
  • 南美TCR-T疗法市场
  • 非洲TCR-T疗法市场

第11章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析
    • 竞争对手之间的竞争
    • 买方的议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 新进入者的威胁
  • 市占率分析

第十二章：机会与策略分析

  • 价值链分析
  • 成长机会分析
    • 按类型分類的成长机会
    • 按应用分類的成长机会
  • 全球TCR-T疗法市场的新趋势
  • 战略分析
    • 新产品开发
    • 认证和许可
    • 合併、收购、协议、合作和合资企业

第十三章 价值链主要企业的公司简介

  • Competitive Analysis
  • Athenex
  • Xiangxue Pharmaceutical（Xiangxue Precision）
  • Hengrui Yuanzheng
  • Eureka Therapeutics
  • Wuxi Juno
  • Shenzhen Inno Immunity
  • Shenzhen Binde Bio

第十四章 附录

  • 图表目录
  • 表格列表
  • 调查方法
  • 免责声明
  • 版权
  • 简称和技术单位

The future of the global tcr-t therapy market looks promising with opportunities in the refractory relapsed melanoma, synovial sarcoma, multiple myeloma, lung cancer and other markets. The global tcr-t therapy market is expected to grow with a CAGR of 12.1% from 2025 to 2031. The major drivers for this market are increase in funding for immuno-oncology and rising advancements in genetic engineering techniques.

  • Lucintel forecasts that, within the type category, autologous is expected to witness higher growth over the forecast period.
  • Within the application category, refractory relapsed melanoma is expected to witness the highest growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the TCR-T Therapy Market

The TCR-T therapy market is evolving with emerging trends that are reshaping the landscape of cancer treatment. These trends are largely driven by advancements in technology, personalized medicine, and growing research into immune-based therapies. Below are five key trends that are transforming the TCR-T therapy market.

  • Personalized Cancer Treatment: TCR-T therapy is moving toward a more personalized approach where each patient's unique cancer profile is used to create targeted therapies. This trend involves isolating specific tumor antigens that are unique to a patient's cancer cells and developing T-cells that are engineered to target these antigens. As the precision of TCR-T therapies improves, treatments become more effective, minimizing side effects and increasing the likelihood of successful outcomes.
  • Increased Focus on Solid Tumors: While TCR-T therapy has traditionally been more successful in treating blood cancers, researchers are increasingly focusing on solid tumors. Solid tumors present a more significant challenge due to their complex microenvironments and the difficulty of targeting antigens effectively. However, ongoing innovations in TCR-T technology are making it possible to target solid tumors like lung, breast, and colorectal cancers, significantly expanding the potential applications of TCR-T therapy in cancer treatment.
  • Expansion of Global Clinical Trials: The expansion of clinical trials is another major trend in the TCR-T therapy market. With increased collaboration between biotech firms, academic institutions, and regulatory bodies, clinical trials are growing in number and scope, especially in emerging markets such as China and India. Clinical trials are crucial for demonstrating the safety and efficacy of TCR-T therapies, and as more trials are conducted, the path to approval and widespread adoption becomes clearer.
  • Integration of TCR-T Therapy with Other Immunotherapies: TCR-T therapy is increasingly being combined with other forms of immunotherapy, such as CAR-T therapy, immune checkpoint inhibitors, and cancer vaccines. The goal is to enhance the overall effectiveness of treatment by targeting multiple pathways simultaneously. By combining different immunotherapy approaches, the immune system can be more effectively activated to fight cancer, potentially leading to more durable and long-lasting responses in patients.
  • Advancements in Manufacturing and Scalability: One of the key challenges with TCR-T therapy is the complex and costly process of manufacturing personalized T-cells. However, there are ongoing advancements in the scalability of T-cell production, including the use of automation and artificial intelligence to streamline the process. These advancements are expected to lower the cost of production and make TCR-T therapy more widely available, thereby expanding its reach to a larger patient population.

The TCR-T therapy market is being reshaped by trends like personalized treatment, the focus on solid tumors, global clinical trials, combination therapies, and advancements in manufacturing. These trends promise to improve the accessibility, efficacy, and affordability of TCR-T therapy, bringing it closer to becoming a mainstream cancer treatment option.

Recent Developments in the TCR-T Therapy Market

The TCR-T therapy market is experiencing rapid growth, driven by advancements in research, clinical trials, and regulatory approvals. In recent years, significant developments have been made in enhancing the effectiveness and accessibility of TCR-T therapies. Below are five key developments that have shaped the current landscape of the TCR-T therapy market.

  • FDA Approval of TCR-T Therapies: The U.S. Food and Drug Administration (FDA) has recently approved several TCR-T therapies for use in treating blood cancers like melanoma and leukemia. These approvals mark a critical step forward in the commercialization of TCR-T therapy, providing patients with access to cutting-edge treatments. The FDA's approval process for TCR-T therapies has been accelerated, particularly for life-threatening cancers, reflecting the growing recognition of the technology's potential.
  • Breakthroughs in Solid Tumor Treatment: Significant progress has been made in adapting TCR-T therapies for solid tumors. Historically, TCR-T therapies have been more effective for treating hematological cancers, but new strategies are emerging to overcome the challenges posed by solid tumors. Clinical trials focusing on cancers like lung, colorectal, and pancreatic are showing promising results, which could vastly expand the market for TCR-T therapy and make it an option for a broader patient base.
  • International Collaborations for TCR-T Development: International partnerships are becoming increasingly common in the development of TCR-T therapies. Collaboration between biotech firms, academic institutions, and healthcare providers is helping to streamline the clinical trial process and share knowledge and resources. These partnerships are also helping to reduce the cost of TCR-T development, making the therapy more affordable and accessible. Key collaborations between companies in the U.S., China, and Europe are accelerating global progress in the field.
  • Development of Allogeneic TCR-T Therapies: A major development in the TCR-T market is the movement toward allogeneic TCR-T therapies. These therapies use T-cells from healthy donors rather than the patient's own T-cells. This approach has the potential to reduce manufacturing costs and make TCR-T therapy more widely available. The development of off-the-shelf allogeneic TCR-T products is an area of significant research, as it could drastically improve the scalability and affordability of the therapy.
  • Advances in TCR-T Manufacturing Technologies: Advancements in manufacturing technologies are improving the efficiency and cost-effectiveness of TCR-T therapy production. New techniques, including automation and cell-culture innovations, are streamlining the process of growing and modifying T-cells. These advances are expected to address the current challenges of scalability and reduce the cost of production, ultimately making TCR-T therapies more accessible to a larger patient population.

Recent developments in the TCR-T therapy market, such as FDA approvals, breakthroughs in solid tumor treatment, international collaborations, the development of allogeneic therapies, and advancements in manufacturing, are reshaping the future of cancer treatment. These developments are helping to drive the widespread adoption of TCR-T therapy, bringing it closer to becoming a viable option for more patients worldwide.

Strategic Growth Opportunities in the TCR-T Therapy Market

The TCR-T therapy market is expected to grow substantially in the coming years, with several strategic growth opportunities emerging across key applications. These opportunities are driven by advancements in research, regulatory support, and the increasing demand for personalized cancer treatments. Below are five key growth opportunities in the TCR-T therapy market.

  • Expansion of TCR-T Applications in Oncology: The primary application for TCR-T therapy is in oncology, where it is increasingly being used to treat a range of cancers, including both hematological and solid tumors. There is substantial growth potential in expanding TCR-T therapy applications across different cancer types, particularly in solid tumors. As research continues to progress, more types of cancer will be targeted, providing a broader market opportunity for TCR-T therapies.
  • Global Market Penetration: With the increasing global recognition of TCR-T therapy's potential, there is significant growth potential in expanding its availability worldwide. Emerging markets, including China, India, and Latin America, present untapped opportunities. Regulatory approvals, clinical trials, and strategic partnerships will be key to accessing these markets and making TCR-T therapies available to a larger patient population.
  • Combination Therapies with Other Immunotherapies: Combining TCR-T therapy with other immunotherapies, such as CAR-T therapy, immune checkpoint inhibitors, and cancer vaccines, presents a growth opportunity. This combination approach has the potential to enhance the effectiveness of treatment and provide more durable responses in patients. As new combination therapies are developed, the market for TCR-T therapy will expand.
  • Adoption in Personalized Medicine: As the shift toward personalized medicine continues, TCR-T therapy stands to benefit from being at the forefront of this movement. Personalized cancer treatments that are tailored to an individual's genetic profile will enhance the effectiveness of TCR-T therapies. By focusing on patient-specific antigens and cancer profiles, TCR-T therapies will become more customized, which is expected to improve patient outcomes and expand the market.
  • Investment in Manufacturing Innovations: The development of scalable and cost-effective manufacturing solutions is critical for the growth of TCR-T therapy. Advances in biomanufacturing, automation, and cell-culture technologies are reducing production costs and increasing efficiency. Investment in manufacturing innovations will make TCR-T therapies more widely available, lowering costs and improving market accessibility.

Strategic growth opportunities in the TCR-T therapy market, including expansion into new oncology applications, global market penetration, combination therapies, personalized medicine, and manufacturing innovations, are expected to drive market growth. These opportunities will make TCR-T therapies more accessible and effective, paving the way for their widespread use in cancer treatment.

TCR-T Therapy Market Driver and Challenges

The TCR-T therapy market is influenced by several key drivers and challenges, ranging from technological advancements to regulatory factors. Understanding these factors is crucial for stakeholders looking to capitalize on the growth of the market. Below are five major drivers and three key challenges impacting the TCR-T therapy market.

The factors responsible for driving the TCR-T Therapy market include:

1. Technological Advancements in Gene Editing: Advancements in gene-editing technologies, such as CRISPR, are a major driver of the TCR-T therapy market. These technologies allow for precise modifications of T-cells, improving the efficacy of TCR-T therapies. As gene-editing techniques become more refined, the potential applications of TCR-T therapy will expand, allowing for more targeted treatments with fewer side effects.

2. Increased Investment in Cancer Immunotherapy: The growing recognition of immunotherapy's potential is driving investment in TCR-T therapy. Funding from both public and private sectors is increasing, leading to more research and development. This financial support is accelerating the progress of TCR-T therapy, resulting in faster clinical trials and the development of more effective treatments.

3. Regulatory Support for Immunotherapies: Regulatory bodies, such as the FDA and EMA, are providing increasing support for the development and approval of TCR-T therapies. This support includes fast-tracking the approval process for promising therapies and providing funding for clinical trials. Regulatory incentives are accelerating the availability of TCR-T therapies, allowing for quicker commercialization.

4. Growing Demand for Personalized Medicine: Personalized medicine is becoming a cornerstone of modern healthcare, and TCR-T therapy is at the forefront of this movement. As the demand for treatments tailored to individual patients' genetic profiles grows, TCR-T therapy is positioned to play a major role in cancer treatment. The shift toward precision medicine is a key driver for the TCR-T therapy market.

5. Rising Cancer Incidence: The increasing incidence of cancer worldwide is another driver for the TCR-T therapy market. As the global cancer burden grows, the demand for innovative treatments, including TCR-T therapies, increases. This trend is expected to continue as the global population ages and lifestyle factors contribute to higher cancer rates.

Challenges in the TCR-T Therapy market are:

1. High Manufacturing Costs: One of the major challenges with TCR-T therapy is the high cost of manufacturing. The complex process of isolating and modifying T-cells is resource-intensive, making the therapy expensive. As a result, the therapy is not yet widely accessible to all patients. Reducing manufacturing costs is critical for the future scalability of TCR-T therapy.

2. Limited Efficacy in Solid Tumors: While TCR-T therapy has shown promising results in treating blood cancers, its efficacy in solid tumors remains a challenge. Solid tumors have complex microenvironments that can inhibit the effectiveness of TCR-T therapies. Overcoming this challenge is a key area of research that could significantly expand the market.

3. Regulatory Hurdles: Although regulatory support for TCR-T therapy is increasing, the approval process for new therapies is still lengthy and complex. Navigating the regulatory landscape can delay the time-to-market for new treatments. Furthermore, inconsistent regulatory standards across different regions can create barriers to the global adoption of TCR-T therapies.

The TCR-T therapy market is driven by technological advancements, investment in immunotherapy, regulatory support, demand for personalized medicine, and the rising incidence of cancer. However, challenges such as high manufacturing costs, limited efficacy in solid tumors, and regulatory hurdles need to be addressed for the market to reach its full potential. By overcoming these challenges, TCR-T therapy has the potential to revolutionize cancer treatment.

List of TCR-T Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies tcr-t therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the tcr-t therapy companies profiled in this report include-

  • Athenex
  • Xiangxue Pharmaceutical (Xiangxue Precision)
  • Hengrui Yuanzheng
  • Eureka Therapeutics
  • Wuxi Juno
  • Shenzhen Inno Immunity
  • Shenzhen Binde Bio

TCR-T Therapy Market by Segment

The study includes a forecast for the global tcr-t therapy market by type, application, and region.

TCR-T Therapy Market by Type [Value from 2019 to 2031]:

  • Autologous
  • Allogeneic

TCR-T Therapy Market by Application [Value from 2019 to 2031]:

  • Refractory Relapsed Melanoma
  • Synovial Sarcoma
  • Multiple Myeloma
  • Lung Cancer
  • Others

TCR-T Therapy Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the TCR-T Therapy Market

TCR-T (T-cell receptor-engineered T-cell) therapy is a promising cancer treatment that is revolutionizing immunotherapy. It involves modifying a patient's own T-cells to recognize and target cancer cells more effectively. With advancements in genetic engineering, enhanced understanding of tumor antigens, and breakthroughs in clinical trials, TCR-T therapy is gaining traction worldwide. In countries like the United States, China, Germany, India, and Japan, the TCR-T therapy market is evolving rapidly, driven by both scientific innovation and increasing demand for personalized medicine. Below are some of the key recent developments in the TCR-T therapy market in these countries.

  • United States: In the United States, TCR-T therapy is witnessing significant progress, particularly in the oncology sector. Several biotech companies and academic institutions are leading the charge, with many ongoing clinical trials targeting solid tumors and hematological cancers. Key advancements include the development of next-generation TCR-T therapies that are more effective at targeting specific tumor antigens. The U.S. Food and Drug Administration (FDA) has accelerated the approval process for certain TCR-T therapies, facilitating market access. Furthermore, partnerships between biotech firms and pharmaceutical companies are pushing the therapy closer to commercialization, making it a central area of focus for cancer treatment innovation.
  • China: China is investing heavily in the development of TCR-T therapies, and the market has seen substantial growth in the past few years. Chinese biotech companies are conducting clinical trials in collaboration with international partners to develop TCR-T therapies for various cancers, including lung cancer and liver cancer. The Chinese government has also been supportive of cancer immunotherapy research through favorable policies and funding. One notable development is the approval of a few TCR-T therapies for certain blood cancers. Additionally, the scale-up of cell manufacturing facilities is increasing, which is expected to enhance the availability of TCR-T therapies at a larger scale in China
  • Germany: Germany is a hub for research and innovation in TCR-T therapy, with several academic and research institutes focusing on advancing this technology. German biotech companies are actively involved in clinical trials, particularly for the treatment of melanoma, glioblastoma, and other solid tumors. The German regulatory environment is also becoming more conducive to the adoption of TCR-T therapy, with the European Medicines Agency (EMA) working on faster approvals for promising therapies. Germany is also seeing an increase in public-private collaborations to accelerate the development of TCR-T therapies, which is contributing to a more robust clinical and regulatory framework for these treatments
  • India: In India, TCR-T therapy is in the early stages of development, but the market is witnessing growing interest from both researchers and patients. The Indian government is investing in medical research, and various private and public institutions are collaborating on clinical trials of TCR-T therapies for cancer treatment. Additionally, India's large patient pool provides an opportunity for conducting clinical trials at a lower cost, making it an attractive destination for international biotech companies. While the technology is still in its nascent stages, India's regulatory body, the Central Drugs Standard Control Organization (CDSCO), is gradually opening up to innovations in immunotherapy.
  • Japan: Japan is one of the leading countries in adopting and advancing TCR-T therapy, particularly in the oncology field. Japanese biotech companies are focusing on TCR-T therapies for cancers such as colorectal cancer, lung cancer, and leukemia. In 2022, Japan's Ministry of Health, Labour, and Welfare (MHLW) approved the first TCR-T therapy for clinical use, which marked a significant milestone. The Japanese government has implemented supportive policies to accelerate the development of immunotherapies, and public-private partnerships are becoming increasingly common. Furthermore, Japan's advanced healthcare infrastructure and patient-focused treatment options make it an attractive market for TCR-T therapy.

Features of the Global TCR-T Therapy Market

  • Market Size Estimates: Tcr-t therapy market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Tcr-t therapy market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Tcr-t therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the tcr-t therapy market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the tcr-t therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the tcr-t therapy market by type (autologous and allogeneic), application (refractory relapsed melanoma, synovial sarcoma, multiple myeloma, lung cancer, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global TCR-T Therapy Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Autologous: Trends and Forecast (2019-2031)
  • 4.4 Allogeneic: Trends and Forecast (2019-2031)

5. Global TCR-T Therapy Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Refractory Relapsed Melanoma: Trends and Forecast (2019-2031)
  • 5.4 Synovial Sarcoma: Trends and Forecast (2019-2031)
  • 5.5 Multiple Myeloma: Trends and Forecast (2019-2031)
  • 5.6 Lung Cancer: Trends and Forecast (2019-2031)
  • 5.7 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global TCR-T Therapy Market by Region

7. North American TCR-T Therapy Market

  • 7.1 Overview
  • 7.2 North American TCR-T Therapy Market by type
  • 7.3 North American TCR-T Therapy Market by application
  • 7.4 United States TCR-T Therapy Market
  • 7.5 Mexican TCR-T Therapy Market
  • 7.6 Canadian TCR-T Therapy Market

8. European TCR-T Therapy Market

  • 8.1 Overview
  • 8.2 European TCR-T Therapy Market by type
  • 8.3 European TCR-T Therapy Market by application
  • 8.4 German TCR-T Therapy Market
  • 8.5 French TCR-T Therapy Market
  • 8.6 Spanish TCR-T Therapy Market
  • 8.7 Italian TCR-T Therapy Market
  • 8.8 United Kingdom TCR-T Therapy Market

9. APAC TCR-T Therapy Market

  • 9.1 Overview
  • 9.2 APAC TCR-T Therapy Market by type
  • 9.3 APAC TCR-T Therapy Market by application
  • 9.4 Japanese TCR-T Therapy Market
  • 9.5 Indian TCR-T Therapy Market
  • 9.6 Chinese TCR-T Therapy Market
  • 9.7 South Korean TCR-T Therapy Market
  • 9.8 Indonesian TCR-T Therapy Market

10. ROW TCR-T Therapy Market

  • 10.1 Overview
  • 10.2 ROW TCR-T Therapy Market by type
  • 10.3 ROW TCR-T Therapy Market by application
  • 10.4 Middle Eastern TCR-T Therapy Market
  • 10.5 South American TCR-T Therapy Market
  • 10.6 African TCR-T Therapy Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global TCR-T Therapy Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Athenex
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Xiangxue Pharmaceutical (Xiangxue Precision)
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Hengrui Yuanzheng
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Eureka Therapeutics
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Wuxi Juno
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Shenzhen Inno Immunity
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Shenzhen Binde Bio
    • Company Overview
    • TCR-T Therapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global TCR-T Therapy Market
  • Figure 2.1: Usage of TCR-T Therapy Market
  • Figure 2.2: Classification of the Global TCR-T Therapy Market
  • Figure 2.3: Supply Chain of the Global TCR-T Therapy Market
  • Figure 3.1: Driver and Challenges of the TCR-T Therapy Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global TCR-T Therapy Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global TCR-T Therapy Market ($B) by Type
  • Figure 4.3: Forecast for the Global TCR-T Therapy Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Autologous in the Global TCR-T Therapy Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Allogeneic in the Global TCR-T Therapy Market (2019-2031)
  • Figure 5.1: Global TCR-T Therapy Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global TCR-T Therapy Market ($B) by Application
  • Figure 5.3: Forecast for the Global TCR-T Therapy Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Refractory Relapsed Melanoma in the Global TCR-T Therapy Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Synovial Sarcoma in the Global TCR-T Therapy Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Multiple Myeloma in the Global TCR-T Therapy Market (2019-2031)
  • Figure 5.7: Trends and Forecast for Lung Cancer in the Global TCR-T Therapy Market (2019-2031)
  • Figure 5.8: Trends and Forecast for Others in the Global TCR-T Therapy Market (2019-2031)
  • Figure 6.1: Trends of the Global TCR-T Therapy Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global TCR-T Therapy Market ($B) by Region (2025-2031)
  • Figure 7.1: North American TCR-T Therapy Market by type in 2019, 2024, and 2031
  • Figure 7.2: Trends of the North American TCR-T Therapy Market ($B) by type (2019-2024)
  • Figure 7.3: Forecast for the North American TCR-T Therapy Market ($B) by type (2025-2031)
  • Figure 7.4: North American TCR-T Therapy Market by application in 2019, 2024, and 2031
  • Figure 7.5: Trends of the North American TCR-T Therapy Market ($B) by application (2019-2024)
  • Figure 7.6: Forecast for the North American TCR-T Therapy Market ($B) by application (2025-2031)
  • Figure 7.7: Trends and Forecast for the United States TCR-T Therapy Market ($B) (2019-2031)
  • Figure 7.8: Trends and Forecast for the Mexican TCR-T Therapy Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Canadian TCR-T Therapy Market ($B) (2019-2031)
  • Figure 8.1: European TCR-T Therapy Market by type in 2019, 2024, and 2031
  • Figure 8.2: Trends of the European TCR-T Therapy Market ($B) by type (2019-2024)
  • Figure 8.3: Forecast for the European TCR-T Therapy Market ($B) by type (2025-2031)
  • Figure 8.4: European TCR-T Therapy Market by application in 2019, 2024, and 2031
  • Figure 8.5: Trends of the European TCR-T Therapy Market ($B) by application (2019-2024)
  • Figure 8.6: Forecast for the European TCR-T Therapy Market ($B) by application (2025-2031)
  • Figure 8.7: Trends and Forecast for the German TCR-T Therapy Market ($B) (2019-2031)
  • Figure 8.8: Trends and Forecast for the French TCR-T Therapy Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the Spanish TCR-T Therapy Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Italian TCR-T Therapy Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the United Kingdom TCR-T Therapy Market ($B) (2019-2031)
  • Figure 9.1: APAC TCR-T Therapy Market by type in 2019, 2024, and 2031
  • Figure 9.2: Trends of the APAC TCR-T Therapy Market ($B) by type (2019-2024)
  • Figure 9.3: Forecast for the APAC TCR-T Therapy Market ($B) by type (2025-2031)
  • Figure 9.4: APAC TCR-T Therapy Market by application in 2019, 2024, and 2031
  • Figure 9.5: Trends of the APAC TCR-T Therapy Market ($B) by application (2019-2024)
  • Figure 9.6: Forecast for the APAC TCR-T Therapy Market ($B) by application (2025-2031)
  • Figure 9.7: Trends and Forecast for the Japanese TCR-T Therapy Market ($B) (2019-2031)
  • Figure 9.8: Trends and Forecast for the Indian TCR-T Therapy Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Chinese TCR-T Therapy Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the South Korean TCR-T Therapy Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the Indonesian TCR-T Therapy Market ($B) (2019-2031)
  • Figure 10.1: ROW TCR-T Therapy Market by type in 2019, 2024, and 2031
  • Figure 10.2: Trends of the ROW TCR-T Therapy Market ($B) by type (2019-2024)
  • Figure 10.3: Forecast for the ROW TCR-T Therapy Market ($B) by type (2025-2031)
  • Figure 10.4: ROW TCR-T Therapy Market by application in 2019, 2024, and 2031
  • Figure 10.5: Trends of the ROW TCR-T Therapy Market ($B) by application (2019-2024)
  • Figure 10.6: Forecast for the ROW TCR-T Therapy Market ($B) by application (2025-2031)
  • Figure 10.7: Trends and Forecast for the Middle Eastern TCR-T Therapy Market ($B) (2019-2031)
  • Figure 10.8: Trends and Forecast for the South American TCR-T Therapy Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the African TCR-T Therapy Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global TCR-T Therapy Market
  • Figure 11.2: Market Share (%) of Top Players in the Global TCR-T Therapy Market (2024)
  • Figure 12.1: Growth Opportunities for the Global TCR-T Therapy Market by Type
  • Figure 12.2: Growth Opportunities for the Global TCR-T Therapy Market by Application
  • Figure 12.3: Growth Opportunities for the Global TCR-T Therapy Market by Region
  • Figure 12.4: Emerging Trends in the Global TCR-T Therapy Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the TCR-T Therapy Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the TCR-T Therapy Market by Region
  • Table 1.3: Global TCR-T Therapy Market Parameters and Attributes
  • Table 3.1: Trends of the Global TCR-T Therapy Market (2019-2024)
  • Table 3.2: Forecast for the Global TCR-T Therapy Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global TCR-T Therapy Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global TCR-T Therapy Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global TCR-T Therapy Market (2025-2031)
  • Table 4.4: Trends of Autologous in the Global TCR-T Therapy Market (2019-2024)
  • Table 4.5: Forecast for Autologous in the Global TCR-T Therapy Market (2025-2031)
  • Table 4.6: Trends of Allogeneic in the Global TCR-T Therapy Market (2019-2024)
  • Table 4.7: Forecast for Allogeneic in the Global TCR-T Therapy Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global TCR-T Therapy Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global TCR-T Therapy Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global TCR-T Therapy Market (2025-2031)
  • Table 5.4: Trends of Refractory Relapsed Melanoma in the Global TCR-T Therapy Market (2019-2024)
  • Table 5.5: Forecast for Refractory Relapsed Melanoma in the Global TCR-T Therapy Market (2025-2031)
  • Table 5.6: Trends of Synovial Sarcoma in the Global TCR-T Therapy Market (2019-2024)
  • Table 5.7: Forecast for Synovial Sarcoma in the Global TCR-T Therapy Market (2025-2031)
  • Table 5.8: Trends of Multiple Myeloma in the Global TCR-T Therapy Market (2019-2024)
  • Table 5.9: Forecast for Multiple Myeloma in the Global TCR-T Therapy Market (2025-2031)
  • Table 5.10: Trends of Lung Cancer in the Global TCR-T Therapy Market (2019-2024)
  • Table 5.11: Forecast for Lung Cancer in the Global TCR-T Therapy Market (2025-2031)
  • Table 5.12: Trends of Others in the Global TCR-T Therapy Market (2019-2024)
  • Table 5.13: Forecast for Others in the Global TCR-T Therapy Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global TCR-T Therapy Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global TCR-T Therapy Market (2025-2031)
  • Table 7.1: Trends of the North American TCR-T Therapy Market (2019-2024)
  • Table 7.2: Forecast for the North American TCR-T Therapy Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various type in the North American TCR-T Therapy Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various type in the North American TCR-T Therapy Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various application in the North American TCR-T Therapy Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various application in the North American TCR-T Therapy Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States TCR-T Therapy Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican TCR-T Therapy Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian TCR-T Therapy Market (2019-2031)
  • Table 8.1: Trends of the European TCR-T Therapy Market (2019-2024)
  • Table 8.2: Forecast for the European TCR-T Therapy Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various type in the European TCR-T Therapy Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various type in the European TCR-T Therapy Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various application in the European TCR-T Therapy Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various application in the European TCR-T Therapy Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German TCR-T Therapy Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French TCR-T Therapy Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish TCR-T Therapy Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian TCR-T Therapy Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom TCR-T Therapy Market (2019-2031)
  • Table 9.1: Trends of the APAC TCR-T Therapy Market (2019-2024)
  • Table 9.2: Forecast for the APAC TCR-T Therapy Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various type in the APAC TCR-T Therapy Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various type in the APAC TCR-T Therapy Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various application in the APAC TCR-T Therapy Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various application in the APAC TCR-T Therapy Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese TCR-T Therapy Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian TCR-T Therapy Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese TCR-T Therapy Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean TCR-T Therapy Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian TCR-T Therapy Market (2019-2031)
  • Table 10.1: Trends of the ROW TCR-T Therapy Market (2019-2024)
  • Table 10.2: Forecast for the ROW TCR-T Therapy Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various type in the ROW TCR-T Therapy Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various type in the ROW TCR-T Therapy Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various application in the ROW TCR-T Therapy Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various application in the ROW TCR-T Therapy Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern TCR-T Therapy Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American TCR-T Therapy Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African TCR-T Therapy Market (2019-2031)
  • Table 11.1: Product Mapping of TCR-T Therapy Suppliers Based on Segments
  • Table 11.2: Operational Integration of TCR-T Therapy Manufacturers
  • Table 11.3: Rankings of Suppliers Based on TCR-T Therapy Revenue
  • Table 12.1: New Product Launches by Major TCR-T Therapy Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global TCR-T Therapy Market